Retinoic Acid Receptor Gamma – Drugs In Development, 2021

Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) – Retinoic acid receptor gamma (RARG) is a nuclear receptor that is encoded by the RARG gene. RARG bind as heterodimers to the target response elements in response to their ligands (all-trans or 9-cis retinoic acid) and regulate gene expression in various biological processes. In the absence or presence of hormone ligand, acts mainly as an activator of gene expression due to weak binding to co-repressors. It is required for limb bud development.

Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) pipeline Target constitutes close to 18 molecules. The molecules developed by companies in Pre-Registration, Phase III, Phase II, Preclinical and Discovery stages are 2, 4, 3, 7 and 2 respectively. Report covers products from therapy areas Dermatology, Musculoskeletal Disorders, Oncology, Ophthalmology, Respiratory, Gastrointestinal, Genetic Disorders, Immunology, Infectious Disease and Metabolic Disorders which include indications Acne Vulgaris, Bronchopulmonary Dysplasia, Congenital Ichthyosis, Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva), Fibrosis, Hand Dermatitis, Head And Neck Cancer, Inflammatory Bowel Disease, Kaposi Sarcoma, Keratoconjunctivitis Sicca (Dry Eye), Mantle Cell Lymphoma, Retinopathy Of Prematurity, Spondyloarthritis (Spondyloarthropathy), Systemic Lupus Erythematosus and Type 1 Diabetes (Juvenile Diabetes).

The latest report Retinoic Acid Receptor Gamma – Drugs In Development, 2021, outlays comprehensive information on the Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape for Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG)

– The report reviews Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved in Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) targeted therapeutics and enlists all their major and minor projects

– The report assesses Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news and deals related to Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG)Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

ABIONYX Pharma SA

Advent Therapeutics Inc

Avecho Biotechnology Ltd

Bausch Health Companies Inc

Boehringer Ingelheim International GmbH

Galderma SA

Galephar Pharmaceutical Research Inc

Ipsen SA

Lee's Pharmaceutical Holdings Ltd

Orphanix GmbH

Ortho Dermatologics Inc

Promius Pharma LLC

Sveikatal Inc

TherapyX Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) - Overview

Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) - Companies Involved in Therapeutics Development

ABIONYX Pharma SA

Advent Therapeutics Inc

Avecho Biotechnology Ltd

Bausch Health Companies Inc

Boehringer Ingelheim International GmbH

Galderma SA

Galephar Pharmaceutical Research Inc

Ipsen SA

Lee's Pharmaceutical Holdings Ltd

Orphanix GmbH

Ortho Dermatologics Inc

Promius Pharma LLC

Sveikatal Inc

TherapyX Inc

Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) - Drug Profiles

(adapalene + benzoyl peroxide + clindamycin phosphate) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(adapalene + clindamycin hydrochloride) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(benzoyl peroxide + tretinoin) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(TPX-6001 + tretinoin) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

alitretinoin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

alitretinoin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

bexarotene + CD-1530 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

palovarotene - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Antagonize ROR-Gamma for Autoimmune Disorders, Allergies and Spondylosis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules 1 to Agonize Retinoic Acid Receptor Gamma for Musculoskeletal Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Agonize RARG for Fibrosis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Agonize Retinoic Acid Receptor Gamma for Musculoskeletal Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tazarotene - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tazarotene - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tretinoin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tretinoin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tretinoin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

trifarotene - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

vitamin A palmitate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

vitamin A palmitate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) - Dormant Products

Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) - Discontinued Products

Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) - Product Development Milestones

Featured News & Press Releases

Aug 04, 2021: Health Canada approves ARAZLO (Tazarotene) Lotion, 0.045%, first such lotion treatment for acne vulgaris

May 28, 2021: Ipsen confirms U.S. FDA accepts new drug application for Palovarotene as the first potential treatment worldwide for fibrodysplasia ossificans progressiva (FOP)

Apr 22, 2021: Ortho Dermatologics announces statistically significant topline results from second pivotal phase 3 clinical trial evaluating IDP-126 gel in acne vulgaris

Apr 21, 2021: Ortho Dermatologics to present abstract on ARAZLO (tazarotene) Lotion at 2021 American Academy of Dermatology Annual Meeting

Feb 24, 2021: Galderma and Aklief (trifarotene) cream, 0.005% unveil me being me campaign to inspire young people with acne to live life to the fullest

Feb 09, 2021: Lee’s Pharmaceutical Holdings: Update on an investigational dermatology product

Nov 16, 2020: Trifarotene in moderate acne: no study data for the assessment of the added benefit

Sep 10, 2020: Ipsen to present new Insights at ASBMR for potential treatment of ultra-rare disease Fibrodysplasia Ossificans Progressiva (FOP), including global phase III MOVE Trial results

Aug 25, 2020: Ipsen to present results from MOVE, the first global phase III trial in fibrodysplasia ossificans progressiva (FOP), at ASBMR 2020 annual meeting

Jul 23, 2020: Ortho Dermatologics launches ARAZLO (tazarotene) lotion, 0.045%, in the United States

Jun 23, 2020: Ortho Dermatologics launches ARAZLO (tazarotene) lotion, 0.045%, in the United States

Mar 27, 2020: Ipsen to restart dosing of palovarotene in FOP studies

Jan 27, 2020: Ipsen temporarily stops palovarotene dosing in FOP trials

Jan 13, 2020: Ortho Dermatologics announces publication of pivotal phase 3 data on ARAZLO (tazarotene) Lotion, 0.045% in the Journal of Drugs in Dermatology (JDD)

Jan 08, 2020: Certara partners with Galderma in advancing modeling and simulation technology to attain FDA approval of AKLIEF topical Acne cream

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development by Stage of Development, 2021

Number of Products under Development by Therapy Areas, 2021

Number of Products under Development by Indication, 2021

Number of Products under Development by Companies, 2021

Products under Development by Companies, 2021

Products under Development by Companies, 2021 (Contd..1)

Number of Products by Stage and Mechanism of Actions, 2021

Number of Products by Stage and Route of Administration, 2021

Number of Products by Stage and Molecule Type, 2021

Pipeline by ABIONYX Pharma SA, 2021

Pipeline by Advent Therapeutics Inc, 2021

Pipeline by Avecho Biotechnology Ltd, 2021

Pipeline by Bausch Health Companies Inc, 2021

Pipeline by Boehringer Ingelheim International GmbH, 2021

Pipeline by Galderma SA, 2021

Pipeline by Galephar Pharmaceutical Research Inc, 2021

Pipeline by Ipsen SA, 2021

Pipeline by Lee's Pharmaceutical Holdings Ltd, 2021

Pipeline by Orphanix GmbH, 2021

Pipeline by Ortho Dermatologics Inc, 2021

Pipeline by Promius Pharma LLC, 2021

Pipeline by Sveikatal Inc, 2021

Pipeline by TherapyX Inc, 2021

Dormant Products, 2021

Dormant Products, 2021 (Contd..1)

Discontinued Products, 2021

List of Figures

List of Figures

Number of Products under Development by Stage of Development, 2021

Number of Products under Development by Therapy Areas, 2021

Number of Products under Development by Top 10 Indications, 2021

Number of Products by Mechanism of Actions, 2021

Number of Products by Stage and Mechanism of Actions, 2021

Number of Products by Routes of Administration, 2021

Number of Products by Stage and Top 10 Routes of Administration, 2021

Number of Products by Molecule Types, 2021

Number of Products by Stage and Molecule Types, 2021

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports